Tight control for the anti- TNF alpha antibody- treated CD (Crohn's disease) patients with thiopurine intensification determined by the capsule endoscopic appearances of small intestinal rejoins

Not Applicable

• Conditions: s disease; Crohn&#39

• Registration Number: JPRN-UMIN000013078
• Lead Sponsor: Saitama Medical Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-03-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Not provided

Exclusion Criteria

patients refractory with infliximab and adalimumab patients refractory with thiopurine derivatives patients whose WBC titer is under 3000/mm3 pregnant patients patients in the lactation patients has past history of malignancy patients who in not suitable to this study determined by doctors

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
improvement ratio of small intestinal regions evaluated by CECDAI at 6 months

Secondary Outcome Measures

Name	Time	Method
mucosal healing rates of small intestinal regions at 6 months serum CRP titer at 6 months serum anti-TNF alpha concentration at 6 months safety